Turmoil and tensions at FDA after dramatic exit of top drug regulator

The FDA's Center for Drug Evaluation and Research (CDER) has appointed Richard Pazdur as its new director, following a period of significant internal turmoil marked by the ousting of the previous director amid accusations of retaliation and unprecedented discord among top officials. This leadership instability and perceived desperation in filling key roles are concerning for the pharmaceutical industry, which relies on the FDA's stability and predictable review processes. While Pazdur, an internal expert, may help restore confidence, the ongoing upheaval could undermine the agency's credibility and the integrity of drug approvals, posing risks to market predictability.

Analysis

The US FDA's Center for Drug Evaluation and Research (CDER) has appointed Richard Pazdur as its new director, following a period of significant internal upheaval. This appointment comes after the abrupt resignation of former director George Tidmarsh in early November, who faced accusations of retaliation and internal conflict, including opposition to a new rapid drug approval program.

The agency has been plagued by an "unusual" degree of discord, highlighted by the controversial return of Vinay Prasad, chief medical and scientific officer, shortly after his initial resignation. The process of filling the CDER director role was marked by perceived "desperation," with employees viewing the position as a "career killer" amidst the ongoing tumult.

This instability is highly concerning for the pharmaceutical industry, which prioritizes FDA stability and predictable review processes to maintain trust and safety. The current chaos risks undermining the agency's credibility and the integrity of its drug approvals, potentially leading to an environment where "everything is up for grabs."

While Pazdur, a respected oncology expert and FDA insider, possesses "the right qualifications" and may help restore some internal confidence, the underlying systemic issues and leadership tensions persist. The appointment, despite its initial reluctance, offers a potential anchor in a turbulent period, though the broader implications for regulatory predictability remain uncertain.

Key Decisions for Investors

• Monitor the FDA's internal stability and leadership dynamics closely, as ongoing turmoil could introduce unpredictability into drug approval timelines and regulatory policy.
• Assess pharmaceutical and biotech investments for potential increased regulatory scrutiny or delays, particularly for novel therapies or those relying on accelerated approval pathways.
• Consider the resilience of portfolio companies' regulatory affairs capabilities and their ability to navigate a potentially more volatile and less predictable FDA environment.